Home » Repligen Says FDA Cancels Meeting on New Drug
Repligen Says FDA Cancels Meeting on New Drug
Repligen said the FDA canceled an advisory committee meeting to review the company’s new drug application for RG1068, which detects pancreatic-duct abnormalities in patients with pancreatitis, and said it expects the FDA to request additional clinical-trial data.
The Wall Street Journal
The Wall Street Journal
Upcoming Events
-
07May
-
14May
-
30May